Asthika Goonewardene
Stock Analyst at Truist Securities
(1.19)
# 3,264
Out of 4,670 analysts
83
Total ratings
30.67%
Success rate
-11.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Maintains: Buy | $87 → $136 | $90.44 | +50.38% | 5 | Nov 12, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $83 → $97 | $90.19 | +7.55% | 1 | Nov 8, 2024 | |
| EXEL Exelixis | Maintains: Buy | $33 → $38 | $35.61 | +6.71% | 6 | Oct 30, 2024 | |
| IGMS IGM Biosciences | Downgrades: Hold | $24 → $12 | $8.89 | +34.98% | 7 | Oct 1, 2024 | |
| GMAB Genmab | Maintains: Buy | $53 → $50 | $20.65 | +142.13% | 13 | Sep 9, 2024 | |
| STRO Sutro Biopharma | Maintains: Buy | $18 → $15 | $2.51 | +497.61% | 6 | Aug 16, 2024 | |
| ALLO Allogene Therapeutics | Reiterates: Buy | $17 → $14 | $2.21 | +533.48% | 6 | Aug 9, 2024 | |
| RCUS Arcus Biosciences | Maintains: Buy | $50 → $44 | $14.70 | +199.32% | 1 | Jun 24, 2024 | |
| LEGN Legend Biotech | Initiates: Buy | $88 | $40.94 | +114.95% | 1 | Jun 17, 2024 | |
| MRUS Merus | Maintains: Buy | $69 → $88 | $45.49 | +93.45% | 2 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.41 | +183.69% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $2.02 | +840.59% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 → $32 | $16.23 | +97.17% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $26 | $8.55 | +204.09% | 5 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $2.04 | +341.18% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $2.15 | +1,760.47% | 4 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $0.90 | +2,900.00% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $9 | $2.94 | +206.12% | 3 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $26.15 | +358.89% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $2.76 | +2,073.91% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $1.19 | +1,160.50% | 4 | Aug 23, 2022 |
Arcellx
Nov 12, 2024
Maintains: Buy
Price Target: $87 → $136
Current: $90.44
Upside: +50.38%
Gilead Sciences
Nov 8, 2024
Maintains: Hold
Price Target: $83 → $97
Current: $90.19
Upside: +7.55%
Exelixis
Oct 30, 2024
Maintains: Buy
Price Target: $33 → $38
Current: $35.61
Upside: +6.71%
IGM Biosciences
Oct 1, 2024
Downgrades: Hold
Price Target: $24 → $12
Current: $8.89
Upside: +34.98%
Genmab
Sep 9, 2024
Maintains: Buy
Price Target: $53 → $50
Current: $20.65
Upside: +142.13%
Sutro Biopharma
Aug 16, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $2.51
Upside: +497.61%
Allogene Therapeutics
Aug 9, 2024
Reiterates: Buy
Price Target: $17 → $14
Current: $2.21
Upside: +533.48%
Arcus Biosciences
Jun 24, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $14.70
Upside: +199.32%
Legend Biotech
Jun 17, 2024
Initiates: Buy
Price Target: $88
Current: $40.94
Upside: +114.95%
Merus
Jun 4, 2024
Maintains: Buy
Price Target: $69 → $88
Current: $45.49
Upside: +93.45%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.41
Upside: +183.69%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $2.02
Upside: +840.59%
May 16, 2024
Reiterates: Buy
Price Target: $34 → $32
Current: $16.23
Upside: +97.17%
Mar 7, 2024
Maintains: Buy
Price Target: $17 → $26
Current: $8.55
Upside: +204.09%
Feb 29, 2024
Upgrades: Buy
Price Target: $9
Current: $2.04
Upside: +341.18%
Sep 6, 2023
Reiterates: Buy
Price Target: $40
Current: $2.15
Upside: +1,760.47%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $0.90
Upside: +2,900.00%
Aug 17, 2023
Maintains: Buy
Price Target: $6 → $9
Current: $2.94
Upside: +206.12%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $26.15
Upside: +358.89%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $2.76
Upside: +2,073.91%
Aug 23, 2022
Maintains: Buy
Price Target: $19 → $15
Current: $1.19
Upside: +1,160.50%